PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq:PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Related news for (PYPD)
- PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
- BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
- 24/7 Market News Snapshot 09 June, 2025 – PolyPid Ltd. Ordinary Shares (NASDAQ:PYPD)
- PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
- Breaking News: MoBot’s Latest Update as of 06/09/25 07:00 AM